NAD+ guide
This NAD+ guide has to separate four things that get sold as one. NAD+ itself given by drip or injection; nicotinamide riboside taken by mouth; NMN taken by mouth; and plain vitamin B3. They have four different evidence bases and results do not transfer between them169. The short version: the oral trials work biochemically and fail clinically, and the drip has almost no evidence at all.
The short answer
- Is an NAD+ drip an approved medicine? No. Every one sold in a US clinic is a compounded or unapproved preparation124.
- Evidence for the drip: a 2026 systematic review found no outcomes trial of intravenous or intramuscular NAD+ for anti-ageing or wellness at all9.
- Does the infused NAD+ reach your cells? Nobody has measured it. The one human study found it vanished from blood and some left in the urine unchanged815.
- Oral precursors: reliably raise blood NAD+, reliably fail on their own endpoints171820219.
- The documented hazard: FDA reports endotoxin reactions from food-grade NAD+ used to make injections23.
- For tested athletes: the rule is about the drip, not the drug — over 100 mL in 12 hours is a prohibited method7.
The one study of what an infusion actually does
There is exactly one published human pharmacokinetic study of infused NAD+: eight men, 750 mg over six hours. The result surprised its own authors. Nothing changed in the blood for the first two hours — the infused NAD+ was rapidly and completely removed from plasma. By six hours, NAD+ and one of its breakdown products were turning up in the urine, meaning part of the dose left the body unchanged815.
The authors read that pattern as the molecule being cleaved by enzymes in the blood before it ever reaches a cell. It is a large molecule being asked to cross a cell membrane, which is not something it does easily.
And here is the gap that matters most: no human study has ever measured NAD+ inside any tissue after an NAD+ infusion8. Not muscle, not brain, not liver. The entire premise — that a drip raises your cellular NAD+ — has never been tested in a person. One trial was designed to compare blood NAD+ after an NAD+ drip against the alternatives. It enrolled 53 people, has a primary completion date in March 2024, and has never reported anything.
What the drip feels like, and why that matters
The best published description comes from a clinic chart review of six people. They reported moderate to severe stomach symptoms, a faster heart rate and chest pressure during their infusions. The symptoms stopped when the infusion did — but they were bad enough that the drip had to be slowed. NAD+ infusions averaged 97 minutes against 37 minutes for the comparison arm10.
That is the infusion-rate phenomenon clinics manage routinely, and it is a pharmacological effect rather than a contamination problem. It is worth separating from the other hazard below, because they have different causes and different fixes.
The hazard FDA has actually documented
In October 2024 FDA published a notice stating it was aware of compounders using food-grade NAD+ bought from repackagers to make intravenous products2. Food-grade material is not suitable for sterile drugs without proper processing, because of contamination with microbes and endotoxins. FDA then reported receiving adverse event reports after NAD+ injections — severe chills, shaking, vomiting and fatigue, some requiring medical treatment — and said these were consistent with excessive endotoxin23.
A January 2026 warning letter shows what that looks like. Three patients given NAD+ from the same vial developed low blood pressure, uncontrollable shaking, shivers and body aches, and were sent to the emergency room. No finished-product testing had been done before release. An unopened vial from the same lot was later found to contain 3,360 endotoxin units per millilitre.
FDA also recorded that the firm had submitted no adverse event reports and had no documented procedure for doing so3. That is a structural reason to assume the safety picture is more incomplete than it looks, rather than reassuringly quiet.
The two controlled trials of injected NAD+, and their doses
Only two exist. A 180-person trial in heart failure gave 10 mg a day into a vein for seven days; at one month the treated group had a higher ejection fraction, 45.4 against 42.4 per cent. That was the only measure to reach significance — serious cardiac events, hospital admissions, symptom class and the blood marker of heart strain all fell short11. A 38-person trial in sudden hearing loss gave 5 mg a day into muscle and reported clearly better recovery, though its control group got no sham injection, so everyone could tell who was being treated12.
Now the number that reframes both: 5 to 10 mg a day. A wellness-clinic drip is typically 250 to 1200 mg. These trials used somewhere between a twenty-fifth and a hundredth of that dose1112. Whatever they show, they are not evidence about the thing being sold.
Addiction: the biggest claim, the thinnest evidence
NAD+ drips are marketed hard for addiction and withdrawal. Registered trials of intravenous or subcutaneous NAD+ for substance use disorder, alcohol use disorder or detoxification: zero13.
The published basis is two papers from one group reporting the identical p-values on the identical fifty patients — two write-ups of one dataset. Both are uncontrolled, unblinded, and use self-reported scores collected by a counsellor from people simultaneously enrolled in a dependency treatment programme. And the infusion was NAD+ combined with amino acids and a vitamin mixture, so nothing observed can be attributed to NAD+ at all13.
The oral evidence, which is real and mostly negative
This is where the actual science is, and it deserves a fair hearing. Around thirty randomised trials of nicotinamide riboside and fifteen of NMN exist. They reliably show one thing: taking these by mouth raises blood NAD+, often two to five fold. That is genuine target engagement.
What happens next is the problem. The cleanest test is a long-COVID trial: 2000 mg a day for 24 weeks raised blood NAD+ two and a half to three times, and then found no difference from placebo in cognition on any of three measures, nor in fatigue, sleep, anxiety or depression21. A 12-week trial using a proper insulin clamp found nothing. Six months of NMN in older adults with diabetes did not improve grip strength or walking speed171820219.
The most-cited positive result, an NMN trial in prediabetic women, rests on comparing each group against itself rather than against the other — which is not the test that establishes an effect — and its analysis is disputed in print by a technical comment in the same journal19.
Something else worth knowing: industry entanglement is the norm here rather than the exception, across the infusion study, the tolerability study and most of the oral trials8101716. That is disclosed rather than hidden, and it is a reason to read framing carefully rather than to throw out the data.
Where the enthusiasm comes from
Eighty rodent studies, and many of them found real benefit: metabolic, mitochondrial, inflammatory and functional9. That is a substantial body of work and it is why serious people are interested.
The only formal safety package for injected NAD+ is also in animals. In dogs, 3 mg/kg was the safe dose; at 10 and 30 mg/kg heart rate rose, two intervals in the heart tracing shortened and blood pressure fell22. Repeated injection into muscle in rats caused injection-site and nerve lesions that reversed. That package was designed for a 5 to 100 mg human product, not for gram-scale drips.
The longest published human exposure to injected NAD+ is about two weeks. There is no chronic safety study, no registry and no surveillance system for compounded NAD+2220.
Two regulatory points worth having right
NMN's status reversed. In 2022 FDA said NMN could not be sold as a dietary supplement, because it had been authorised for investigation as a new drug first. On 29 September 2025 FDA reversed that: NMN had in fact been marketed as a supplement since 2017, before that authorisation. FDA explained its own error — the drug it found under a code name was not recognised as being NMN — and formally set the 2022 letters aside in December 20256. Anything still saying FDA has banned NMN is describing a position FDA abandoned.
In sport, the rule is about the bag. NAD+, NMN, riboside and niacin are not named anywhere on the prohibited list. That is not the relevant rule. Any intravenous infusion totalling more than 100 mL in a 12-hour period is a prohibited method at all times, with only three exceptions — hospital treatment, surgery, diagnostic investigation7. A wellness drip is none of those, and a typical one is 250 to 1000 mL.
Where the rest of the detail lives
The interactive library on the homepage carries the fuller reference entry for NAD+, including the amounts and handling notes it holds for every compound. That is general reference information, the same for every visitor.
References
These are the sources behind this page, listed so you can read them yourself rather than take our word for it. Animal and laboratory findings do not establish that something works or is safe in people. Doses and protocols shown on a study card are that study's research parameters, not recommendations. PepCaddie does not sell peptides and does not choose a dose for anyone; this is educational material and it does not replace a qualified healthcare professional.
The only study of what an infusion actually does
2019Human observational study
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
The finding was not what anyone expected. Nothing changed in the blood for the first two hours: the infused NAD+ was rapidly and completely removed from plasma. By six hours, NAD+ and one of its breakdown products were appearing in the urine, meaning part of the dose left the body unchanged. The authors read the pattern as the peptide being cleaved by enzymes in the blood before it reaches cells. No adverse events occurred at this deliberately slow rate.
Limitation: Eight men in the active arm, measuring blood and urine only. No tissue was sampled, so the study cannot say whether any infused NAD+ reached a cell anywhere. It was funded by a company that sells the therapy and run at a clinic that provides it, which the authors disclose.
Open pilot with a small saline comparison group, not blindedView study: The only study of what an infusion actually does
The systematic review, and its one decisive sentence
2026Systematic review
The review states the position plainly: no eligible outcomes trial evaluated intravenous or intramuscular NAD+ itself for anti-ageing or wellness indications. What it did find was that oral nicotinamide riboside and NMN consistently hit their biochemical target and were well tolerated, while their effects on the outcomes that would matter to a person were heterogeneous and often null. The rodent literature, 80 studies of it, frequently showed benefit.
Limitation: A review can only summarise what exists. Its author discloses owning a services company for an aesthetics clinic, noting that the clinic does not offer NAD+ infusions.
Systematic review of 113 studiesView study: The systematic review, and its one decisive sentence
What the drip actually feels like
2026Human observational study
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
The people given NAD+ reported moderate to severe stomach symptoms, a faster heart rate and chest pressure during their infusions. Symptoms resolved when the infusion finished, but they were bad enough that the drip had to be slowed: NAD+ infusions averaged 97 minutes against 37 minutes for the comparison. This is the clearest published description of the infusion-rate problem that clinics manage by slowing the drip.
Limitation: Six people in the NAD+ group, reviewed after the fact, with no randomisation and no control. The blood-test changes it reports are many comparisons on tiny groups and should be read as noise. Every author was employed by the wellness chain whose clients were reviewed.
Retrospective review of clinic records, no control groupView study: What the drip actually feels like
The largest controlled trial of intravenous NAD+
2026Human randomised trial
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
At one month the treated group had a higher ejection fraction than placebo, 45.4 against 42.4 per cent. That was the only measure to reach significance. The rate of serious cardiac events, hospital admissions, symptom class and the blood marker of heart strain all pointed the same direction without reaching it, and no structural measure differed.
Limitation: A three-point difference in one imaging measure, reported as post-treatment values rather than adjusted change from baseline, while every clinical endpoint failed. The dose also matters enormously here: 10 mg a day is between a twenty-fifth and a hundredth of a typical wellness-clinic drip, so this is not evidence about one.
Single-centre randomised placebo-controlled trialView study: The largest controlled trial of intravenous NAD+
An injected trial in sudden hearing loss
2026Human randomised trial
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Hearing improved more in the treated group, 40.2 against 23.1 decibels, with a higher effective response rate and shorter recovery time. It is one of only two controlled trials of injected NAD+ in the whole literature.
Limitation: Despite being called double-blind, the control group received standard treatment with no sham injection, so patients and staff could tell who was being injected daily. The trial was registered after it started and its registered dates do not match the enrolment window in the paper. It was funded by the manufacturer of the product tested, which nonetheless declares no conflict of interest. A critical letter has since been published about it.
Randomised controlled trial, described as double-blindView study: An injected trial in sudden hearing loss
The entire published basis for the addiction claim
2022Human observational study
Craving, anxiety and depression scores fell sharply from before to after treatment. This paper and a 2024 one by the same group report the identical p-values on the identical fifty patients, so they are two write-ups of one dataset rather than two studies. The infusion was NAD+ combined with amino acids and a vitamin mixture.
Limitation: Self-reported scores on an unblinded scale collected by a counsellor, in people simultaneously in a dependency treatment programme, with no control group. Nothing in it can be attributed to NAD+ specifically, because the infusion contained several other active ingredients. The senior author holds patents on the amino-acid component.
Uncontrolled case series, not randomised, not blindedView study: The entire published basis for the addiction claim
A single case, honestly reported
2026Case report or case series
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
A woman having NAD+ infusions for cosmetic reasons reported rapid pain relief and later improvement in swelling and function, and nine months on her ultrasound showed no active inflammation. It is included here because it is an unusually careful case report: the authors state themselves that prior medication, concurrent life changes and the uncontrolled design prevent any causal conclusion, and describe it as hypothesis-generating.
Limitation: One person, with a previous disease-modifying drug in the background and several other things changing at the same time. The authors say plainly that no causal inference is possible.
Case reportView study: A single case, honestly reported
A completed comparison that has never reported
2024Registered clinical trial
This trial compared intravenous NAD+ against intravenous nicotinamide riboside, oral riboside and saline, and measured total NAD in blood spots along with the tolerable infusion rate. Its record gives a primary completion date in March 2024 and 53 participants actually enrolled. It has posted no results, no publication has appeared, and its registry status has not been updated since.
Limitation: An unreported trial establishes nothing. It is listed here because it is the one study designed to answer whether an NAD+ drip raises blood NAD+ more than the alternatives, and its silence is part of the evidence picture.
Randomised, double-masked, four arms including salineView study: A completed comparison that has never reported
The one intravenous NMN study
2022Human observational study
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
A single intravenous dose of NMN, a precursor rather than NAD+ itself, did not disturb heart tracings, pulse, blood pressure or organ markers, raised blood NAD+ and was followed by a fall in blood triglycerides.
Limitation: Ten fasted people, one dose, no placebo and no control, so a fall in triglycerides over a few hours cannot be attributed to the infusion. Six of the eight authors are employees of the sponsor.
Single-arm, single-dose, uncontrolledView study: The one intravenous NMN study
The largest oral trial: biomarker only
2019Human randomised trial
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
The largest randomised trial of oral nicotinamide riboside. It established what this whole literature establishes well: taking it by mouth raises blood NAD+ in a dose-related way and is tolerated over two months. It did not measure whether anything about the participants improved.
Limitation: The endpoints were a blood measurement and side effects. A rise in blood NAD+ is target engagement, not benefit, and this trial was not designed to find benefit. It was funded by the manufacturer of the product tested.
Randomised, double-blind, placebo-controlled, three dose levelsView study: The largest oral trial: biomarker only
Null on insulin sensitivity, measured properly
2018Human randomised trial
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Twelve weeks of a high oral dose, measured with a clamp study, which is the proper way to measure insulin sensitivity rather than a blood-sugar proxy. It found nothing. This is the cleanest negative in the oral literature and it used one of the highest doses tested.
Limitation: Men with obesity rather than a general population, over twelve weeks. It is a well-conducted trial reporting a null result, which is a reason to take it seriously rather than to discount it.
Randomised placebo-controlled trial using an insulin clampView study: Null on insulin sensitivity, measured properly
The most-cited positive NMN trial, and its dispute
2021Human randomised trial
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
This is the trial most often cited as proof NMN works. Insulin-stimulated glucose disposal and muscle insulin signalling increased after NMN and did not change after placebo. The phrasing matters: that is a comparison of each group against itself, not a comparison between the groups, which is the test that would establish an effect. Blood NAD+ in immune cells did not rise further.
Limitation: Twenty-five people, with the headline resting on a within-group framing. A technical comment published in the same journal disputes the analysis, and the authors published a response, so this is a live disagreement rather than a settled result.
Randomised placebo-controlled trial using an insulin clampView study: The most-cited positive NMN trial, and its dispute
Null on strength and walking speed
2023Human randomised trial
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Six months of oral NMN in exactly the population the anti-ageing claim targets: older people with diabetes and reduced physical performance. It was safe, and it did not improve grip strength or walking speed.
Limitation: Fourteen people is too small to rule out a modest effect. It is one of the longest oral trials in the literature, which is itself a comment on how short the rest are.
Randomised trialView study: Null on strength and walking speed
NAD+ tripled, and nothing changed
2025Human randomised trial
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
This trial is the cleanest test of the central premise. Blood NAD+ rose between two and a half and three times over six months on a high oral dose. Cognition did not differ from placebo on any of three measures. Neither did fatigue, sleep quality, anxiety or depression. The biochemistry worked and the person did not change.
Limitation: Fifty-eight people with one specific condition, so it cannot speak for everyone. It is included because it did the thing most trials skip: it confirmed the NAD+ rise and then measured whether anything followed.
Randomised placebo-controlled trialView study: NAD+ tripled, and nothing changed
The only formal safety package, and it is in animals
2026Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
In dogs, 3 mg/kg was the safe dose; at 10 and 30 mg/kg heart rate rose, two electrical intervals in the heart tracing shortened and blood pressure fell. Repeated injection into muscle in rats produced injection-site and nerve lesions that reversed. Allergy and blood-cell tests were negative.
Limitation: This package was designed for a 5 to 100 mg injected human product, not for the gram-scale drips sold in wellness clinics, and animal doses do not convert simply to human ones. It is included because it is the only formal safety evaluation of injected NAD+ that exists anywhere.
Formal regulatory-standard toxicology packageView study: The only formal safety package, and it is in animals
Drugs@FDA and DailyMed: no approved NAD+ product by any route. U.S. Food and Drug Administration; 2026.
Official regulatory sourceChecked 2026-09-21
Read FDA's approved-drug and labelling databases at the sourceFDA reminds compounders to use ingredients suitable for sterile compounding. U.S. Food and Drug Administration; 2024.
Official regulatory sourceChecked 2026-09-21
Read FDA on food-grade NAD+ in injections at the sourceWarning letter: GenoGenix LLC (MARCS-CMS 718739). U.S. Food and Drug Administration; 2026.
Official regulatory sourceMARCS-CMS 718739Checked 2026-09-21
Read Three patients to the emergency room from one vial at the sourceWarning letter: ProRx LLC (MARCS-CMS 723704). U.S. Food and Drug Administration; 2026.
Official regulatory sourceMARCS-CMS 723704Checked 2026-09-21
Read A second compounding warning letter at the sourceBulk drug substances nominated for use in compounding under section 503A. U.S. Food and Drug Administration; 2026.
Official regulatory sourceChecked 2026-09-21
Read NAD+'s compounding status: under evaluation at the sourceFDA response to citizen petition FDA-2023-P-0872 on nicotinamide mononucleotide. U.S. Food and Drug Administration, Human Foods Program; 2025.
Official regulatory sourceFDA-2023-P-0872Checked 2026-09-21
Read FDA reversed its position on NMN at the sourceThe 2026 Prohibited List, section M2.2. World Anti-Doping Agency; 2026.
Official regulatory sourceChecked 2026-09-21
Read WADA's rule is about the drip, not the drug at the sourceGrant R, Berg J, Mestayer R, et al.. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD. Frontiers in Aging Neuroscience; 2019.
Human observational studyPMID 31572171 · DOI 10.3389/fnagi.2019.00257Checked 2026-09-21
Read The only study of what an infusion actually does at the sourceGallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews; 2026.
Systematic reviewPMID 41655607 · DOI 10.1016/j.arr.2026.103057Checked 2026-09-21
Read The systematic review, and its one decisive sentence at the sourceReyna K, Heinzen G, Patel N, et al.. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging; 2026.
Human observational studyPMID 41704678 · DOI 10.3389/fragi.2026.1652582Checked 2026-09-21
Read What the drip actually feels like at the sourceYu X, Xu J, Cao J, et al.. Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: a randomized, placebo-controlled trial. American Journal of Cardiovascular Drugs; 2026.
Human randomised trialPMID 40954388 · DOI 10.1007/s40256-025-00764-7Checked 2026-09-21
Read The largest controlled trial of intravenous NAD+ at the sourceGao M, Guan Y, Yue X, et al.. NAD+ enhanced on hearing recovery in sudden sensorineural hearing loss: randomized controlled trial. The Laryngoscope; 2026.
Human randomised trialPMID 41035311 · DOI 10.1002/lary.70173 · NCT05849519Checked 2026-09-21
Read An injected trial in sudden hearing loss at the sourceBlum K, Han D, Baron D, et al.. Nicotinamide adenine dinucleotide (NAD+) and enkephalinase inhibition infusions significantly attenuate psychiatric burden sequelae in substance use disorder in fifty cases. Current Psychiatry Research and Reviews; 2022.
Human observational studyPMID 36118157 · DOI 10.2174/2666082218666220527114427Checked 2026-09-21
Read The entire published basis for the addiction claim at the sourceItani MR, Farhat A, Abou Yehya N, et al.. Symptomatic and ultrasonographic improvement in rheumatoid arthritis temporally associated with intravenous NAD+ therapy: a case report. ACR Open Rheumatology; 2026.
Case report or case seriesPMID 42751848 · DOI 10.1002/acr2.90151Checked 2026-09-21
Read A single case, honestly reported at the sourceThe effects of IV administration of ChromaDex’s Niagen, nicotinamide riboside chloride, as compared to IV administration of NAD+: a randomized, placebo controlled clinical trial. ClinicalTrials.gov (sponsor: Nutraceuticals Research Institute); 2024.
Registered clinical trialNCT06382688Checked 2026-09-21
Read A completed comparison that has never reported at the sourceKimura S, Ichikawa M, Sugawara S, et al.. Nicotinamide mononucleotide is safely metabolized and significantly reduces blood triglyceride levels in healthy individuals. Cureus; 2022.
Human observational studyPMID 36225528 · DOI 10.7759/cureus.28812Checked 2026-09-21
Read The one intravenous NMN study at the sourceConze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports; 2019.
Human randomised trialPMID 31278280 · DOI 10.1038/s41598-019-46120-zChecked 2026-09-21
Read The largest oral trial: biomarker only at the sourceDollerup OL, Christensen B, Svart M, et al.. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. American Journal of Clinical Nutrition; 2018.
Human randomised trialPMID 29992272 · DOI 10.1093/ajcn/nqy132 · NCT02303483Checked 2026-09-21
Read Null on insulin sensitivity, measured properly at the sourceYoshino M, Yoshino J, Kayser BD, et al.. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science; 2021.
Human randomised trialPMID 33888596 · DOI 10.1126/science.abe9985 · NCT03151239Checked 2026-09-21
Read The most-cited positive NMN trial, and its dispute at the sourceAkasaka H, Nakagami H, Sugimoto K, et al.. Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance. Geriatrics and Gerontology International; 2023.
Human randomised trialPMID 36443648 · DOI 10.1111/ggi.14513Checked 2026-09-21
Read Null on strength and walking speed at the sourceWu CY, Reynolds WC, Abril I, et al.. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. eClinicalMedicine; 2025.
Human randomised trialPMID 41357333Checked 2026-09-21
Read NAD+ tripled, and nothing changed at the sourceGu J, Xu J, Yang S, et al.. Non-clinical safety evaluation of coenzyme I (NAD+): a GLP-compliant systematic study. Biomedicine and Pharmacotherapy; 2026.
Animal studyPMID 42748828 · DOI 10.1016/j.biopha.2026.119934Checked 2026-09-21
Read The only formal safety package, and it is in animals at the source